Human CD47/SIRP alpha biochemical binding kit HTRF®
This immune checkpoint assay is designed to identify human CD47/SIRP alpha inhibitors.
- All inclusive kit
- Scalable from 96 to 1536 format
- Validated with reference Ab
Signal-regulatory protein alpha (SIRP-alpha), also known as CD172a, is a cell surface protein expressed mainly by myeloid cells, such as macrophages. Its receptor, CD47, is ubiquitously expressed on the surface of all cells and has been found to be overexpressed in some cancers. CD47 binding to SIRP-alpha delivers a "Do Not Eat Me" signal to macrophages. In the case of a tumor, this signaling aids in tumor evasion of the immune system. Inhibitors of this interaction hold great promise for cancer immunotherapy.
- ACTIVATE T CELL RESPONSE
- IMMUNOTHERAPY TO FIGHT CANCER
- DISCOVER IMMUNE CHECKPOINT BLOCKING DRUGS
The CD47/SIRP binding assay includes human recombinant immune checkpoint partners tagged for detection (CD47 and SIRP alpha) and labelled anti-tag reagents for HTRF detection. Without an inhibitor, CD47 binds to SIRP alpha, and the binding of each detection reagent to its tagged target generates an HTRF signal. In the presence of compound, standard or an antibody blocking the CD47/SIRP alpha interaction, the HTRF signal decreases.
This CD47/SIRP alpha binding assay can be run in a 96- or 384-well low volume white plate (20 µL final). As described here, samples or standards are dispensed directly into the assay plate, and the tagged CD47 & SIRP alpha protein are then added, followed by the dispensing of the HTRF reagents. The reagents labelled with HTRF fluorophores may be pre-mixed and added in a single dispensing step. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.
Inhibitory effect of the blocking standard
Performing an 8-point dose response curve using the blocking standard provided in the kit. The CD47-SIRP alpha interaction is inhibited, with an IC50 of 2.6 nM.
Inhibitory effect of blocking antibodies
The inhibitory effects of three antibodies known to inhibit the CD47-SIRP alpha interaction were tested. The two anti-CD47 antibodies (B6H12 & B6H12.2) were shown to inhibit the interaction, with IC50s of 2.2 & 1.6 nM respectively. The anti-SIRP alpha antibody (SE5A5) disrupted the interaction, with an IC50 of 2.4 nM.
Best practices for pharmacological characterization of PPI inhibitors
Easy pharmacological characterization of PPI modulators. - Technical Notes
HTRF assays handle low- to high affinity protein-protein interactions
Deciphering low- and high affinity interactions - Application Notes
Nuclear receptor ligand identification with HTRF
Monitoring nuclear receptor binding with HTRF assays - Application Notes
HTRF addresses large protein-protein interaction complexes
Challenge large complexes with HTRF assays - Application Notes
How HTRF compares to Western Blot and ELISA
Get the brochure about technology comparison. - Brochures
Virology research solutions using HTRF Protein-Protein Interaction assays
See how peer researchers challenge the viral life cycle with PPI assays - Application Notes
autoimmune diseases therapeutic approaches
Complete autoimmunity review in a single White Paper - Guides
Autoimmune diseases and therapeutic strategies
Check out our new guide featuring valuable insights on autoimmunity - Guides
Plate Reader Requirement
Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.Let's find your reader